KURA — Kura Oncology Cashflow Statement
0.000.00%
- $975.03m
- $435.04m
- $53.88m
- 44
- 25
- 45
- 31
Annual cashflow statement for Kura Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -89.6 | -130 | -136 | -153 | -174 |
| Depreciation | |||||
| Non-Cash Items | 13.2 | 28.6 | 28 | 19.1 | 21.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6.38 | -3.22 | -2.98 | 7.82 | 286 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -69.8 | -105 | -110 | -125 | 134 |
| Capital Expenditures | -2.17 | -1.15 | -0.626 | -0.168 | -0.472 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -97.8 | -126 | 33.3 | 15.7 | -101 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -99.9 | -127 | 32.6 | 15.6 | -102 |
| Financing Cash Flow Items | — | -0.611 | -0.575 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 469 | -3.44 | 38.6 | 94.8 | 154 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 300 | -235 | -38.9 | -14.5 | 187 |